Royal Bank Of Canada began coverage on shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in a research note issued to investors on Thursday, September 14th, Marketbeat Ratings reports. The firm issued an outperform rating on the biotechnology company’s stock.
A number of other research firms also recently weighed in on ENTA. Zacks Investment Research downgraded Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, June 21st. ValuEngine upgraded Enanta Pharmaceuticals from a sell rating to a hold rating in a report on Friday, June 2nd. BidaskClub downgraded Enanta Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 11th. JMP Securities upgraded Enanta Pharmaceuticals from a market perform rating to an outperform rating and set a $40.00 target price on the stock in a report on Tuesday, July 11th. Finally, Robert W. Baird boosted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a neutral rating in a research report on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Enanta Pharmaceuticals presently has an average rating of Buy and an average target price of $36.00.
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at 42.71 on Thursday. Enanta Pharmaceuticals has a 12 month low of $22.17 and a 12 month high of $45.74. The firm’s 50-day moving average price is $41.09 and its 200-day moving average price is $34.67. The company’s market cap is $815.33 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The company had revenue of $7.51 million for the quarter, compared to the consensus estimate of $8.08 million. During the same quarter in the previous year, the business earned ($0.06) EPS. Enanta Pharmaceuticals’s revenue was down 46.3% compared to the same quarter last year. Equities analysts predict that Enanta Pharmaceuticals will post $1.14 EPS for the current fiscal year.
WARNING: “Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives New Coverage from Analysts at Royal Bank Of Canada” was originally published by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://baseballnewssource.com/markets/enanta-pharmaceuticals-inc-enta-receives-new-coverage-from-analysts-at-royal-bank-of-canada/1645659.html.
Hedge funds have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 165.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 492,265 shares of the biotechnology company’s stock valued at $17,712,000 after buying an additional 307,166 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Enanta Pharmaceuticals by 129.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after buying an additional 233,265 shares during the period. State Street Corp lifted its holdings in shares of Enanta Pharmaceuticals by 31.8% during the 1st quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after buying an additional 180,586 shares during the period. ING Groep NV purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth $3,274,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth $1,731,000. 66.07% of the stock is currently owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.